Boston Scientific launches Promus Premier drug-eluting stent in Japan

Boston Scientific's Promus Premier coronary stent--Courtesy of Boston Scientific

Boston Scientific ($BSX) rolled out its Promus Premier next-generation drug-eluting coronary stent system in Japan. The everolimus-releasing platinum-chromium stent is part of the company's sales and marketing strategy as it looks for a blockbuster product to kick-start its revenue growth. "Japan is an important interventional cardiology market, and we believe the launch and success of this stent system in Japan will enhance Boston Scientific's overall growth strategy in the DES [drug eluting stent] market," said interventional cardiology president Kevin Ballinger in a statement. More

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.